Eyepoint, Inc. · NASDAQ:EYPT
Eyepoint — EyePoint Pharmaceuticals — Investor Presentation (January 2020)
27 slides from Eyepoint's investor presentation, Jan 16, 2020
Slide 1: Investor Presentation January 2020
INVESTOR PRESENTATION JANUARY 2020 NASDAQ: EYPT Exhibit 99.1
Slide 2: Safe Harbor Statements
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. This presentation is intended for communication for investors only. Noth
Slide 3: An Emerging Leader in Ophthalmology
AN EMERGING LEADER IN OPHTHALMOLOGY Transitioned into commercial growth company with the launches of YUTIQ® and DEXYCU® in Q1 2019 Veteran executive team with deep experience in commercial product launches and clinical development Strategic focus to become go-to partner for commercialization in opht
Slide 4: Product Pipeline
1 Alimera Sciences, Inc. owns worldwide rights to ILUVIEN® for DME and rights for YUTIQ® for non-infectious posterior uveitis in the EMEA with a royalty payable to Eyepoint. PRODUCT PIPELINE Program Preclin. Phase 1 Phase 2 Phase 3 Commercial Rights DEXYCU® post-operative inflammation WW YUTIQ® thre
Slide 5: Durasert and Verisome: Proven, FDA Approved Technologies
Durasert™ Verisome™ Durasert™ and Verisome™: Proven, FDA Approved Technologies Ocular insert for long-term delivery of small molecules Approved products: YUTIQ® (2018, EyePoint) ILUVIEN® (2012, Alimera) - DME RETISERT ® (2005, B&L) – Uveitis VITRASERT® (1996, B&L) -CMV retinitis Microsphere suspensi
Slide 6: 2019: A Transformational Year
2019: A TRANSFORMATIONAL YEAR YUTIQ® 50 (6-month) regulatory pathway reviewed with FDA with approval pathway clarified EYP-1901 – Durasert™ TKI for wet-AMD advanced into IND enabling studies Durasert™ and Verisome™ technologies positioned for partnering and organic pipeline growth YUTIQ® partnered i
Slide 7: Two Commercial Products Launched in 2019
TWO COMMERCIAL PRODUCTS LAUNCHED IN 2019 Postoperative inflammation following ocular surgery Chronic non-infectious uveitis affecting the posterior segment of the eye 33 dedicated KAMs targeting high-volume ambulatory surgical centers (ASCs) Permanent and specific J-Code with minimal reimbursement i
Slide 8: U.S. Cataract Surgery Very Large and Growing
U.S. Cataract Surgery Very Large and Growing * Based upon company estimates for 2018. Source: imaged from the American Optometric Association. DEXYCU® - Significant Market Opportunity ~$2B Intraocular lens is inserted Intraocular lens is positioned Diseased lens is removed Cataract Surgeries in 2018
Slide 9: Post-cataract Treatment Regimen Requires Multiple Daily Eyedrops
Post-cataract Treatment Regimen Requires Multiple Daily Eyedrops *Source: Vigamox/Besivance product labeling (not specifically indicated for this use, but are commonly prescribed for use). **Source: Prolensa/Bromday product labeling (not specifically indicated for this use, but are commonly prescrib
Slide 10: DEXYCU: First and Only FDA-approved Single-dose Intracameral Steroid
1 Wong V. et al. Pharmacokinetic Study of 10090 in the Anterior Chamber of Rabbits (2013). Note: Refer to the full DEXYCU® product label at www.eyepointpharma.com. DEXYCU® Detectable up to 22 days after single injection(1) Suspension placed behind the iris First and Only FDA-approved Single-dose, Su
Slide 11: DEXYCU Demonstration
DEXYCU DEMONSTRATION Please see video at company website: https://eyepointpharma.com/case-study-series/
Slide 12: Statistically Significant Inflammation Reduction
Statistically Significant Inflammation Reduction Note: Refer to the full DEXYCU® product label at www.eyepointpharma.com. DEXYCU® * *P≤0.05 vs. placebo Day 8 Primary endpoint Placebo (n=80) DEXYCU® (n=156) * * * 3x clearance vs. placebo at day 8 40 percentage point difference vs. placebo (97.5% CI)
Slide 13: IOP Elevation Versus Placebo Not Clinically Significant
% of patients IOP Elevation Versus Placebo Not Clinically Significant Data on file. Phase III Study 13-04. Post hoc analysis. DEXYCU® IOP Intervals on POD 1 IOP Intervals on POD 3 IOP Intervals on POD 8 IOP Intervals on POD 15 % of patients % of patients % of patients
Slide 14: Phase III Study – Safety Results
Phase 3 Study – Safety Results Note: Refer to the full DEXYCU® product label at www.eyepointpharma.com. DEXYCU® Safety, n (%) Placebo N=80 517 mcg N=156 Any TEAE in Study Eye 51 (63.8) 72 (46.2) Any Ocular SAE in Study Eye 0 0 Any Non-ocular SAE 4 (5.0) 4 (2.6) Study Eye AEs Occurring in ³5% of at L
Slide 15: DEXYCU Sales Process
DEXYCU® SALES PROCESS Average Time (weeks) to Account Re-Order 1 Introduce Introduce DEYXCU and its clinical and safety data to target physician Educate Educate the ASC where physician operates about DEXYCU profile Sample Schedule a physician and staff DEXYCU trial and training Order ASC places firs
Slide 16: DEXYCU Launch Progress Update
3Q19 Compared to 2Q19 ASC: Ambulatory Surgical Center DEXYCU® LAUNCH PROGRESS UPDATE Repeat orders from ASCs Increase in customer orders Volume from repeat orders 207% 37% 74% September 2019 Represented the Highest Volume Month for Repeat Orders to Date
Slide 17: DEXYCU Cumulative Orders Since Launch
Month Over Month Growth Accelerating DEXYCU® CUMULATIVE ORDERS SINCE LAUNCH DEXYCU® month over month growth of cumulative orders averaged 62.5% in 3Q19
Slide 18: Market Potential Based on Account Penetration
Market Potential Based on Account Penetration thru 12/31/19 ASC: Ambulatory Surgical Center Data based on internal estimates DEXYCU® DEXYCU Market Potential $2.0B DEXYCU ASCs in-serviced to date $170M ASCs Re-Ordering $105M ASCs Re-Ordering 3+ $95M Value of Current ASC Accounts with 3+ Orders Value
Slide 19: YUTIQ Market
YUTIQ® Market Patients in the U.S. with Chronic Non-infectious Posterior Segment Uveitis ~55K–120K ~30,000 new cases of blindness per year in the U.S. 3rd leading cause of blindness in the U.S. Uveitis is: Inflammation of the Uveal tract (iris, ciliary body, choroid), or adjacent structures (lens, r
Slide 20: YUTIQ Sustained Release of Fluocinolone
YUTIQ® YUTIQ® Is Designed to Deliver a Sustained Release of Fluocinolone for Patients with Chronic Noninfectious Posterior Uveitis for Up To 36 Months Durasert Technology Packaging YUTIQ Placement
Slide 21: Recurrence Rate at Six and Twelve Months vs Sham
Recurrence Rate at Six and Twelve Months vs Sham * Sham includes standard of care. Note: Refer to the full YUTIQ® product label at www.eyepointpharma.com YUTIQ® 4.4x 3.1x p < 0.01 p < 0.01 p < 0.01 p < 0.01 YUTIQ Patients more likely to be recurrence free 2.5x 1.8x YUTIQ Patients more likely to be r
Slide 22: Single Insert Reduced Probability of Uveitis Recurrence Through 36 Months
Single Insert Reduced Probability of Uveitis Recurrence Through 36 Months Note: Sham patients include patients that received rescue therapy. YUTIQ® YUTIQ Median Time to First Recurrence: 1,051 Days 3 years ITT Population
Slide 23: Safety – Select Adverse Events
Safety – Select Adverse Events 1 Includes macular edema and cystoid macular edema 2 Includes eye pain and procedural pain 3 Includes hypotony, intraocular pressure decreased and procedural hypotension Note: Refer to the full YUTIQ® product label at www.eyepointpharma.com YUTIQ® Safety, n (%) YUTIQ®
Slide 24: YUTIQ Launch Progress Update
3Q19 compared to 2Q19 YUTIQ® LAUNCH PROGRESS UPDATE Repeat customers Increase of customer orders Continued Strong Reception of the YUTIQ® Product Profile from Uveitis Specialists Volume from repeat orders 17% 53% 85%
Slide 25: YUTIQ Cumulative Orders Since Launch
YUTIQ® CUMULATIVE ORDERS SINCE LAUNCH YUTIQ® month over month growth of cumulative orders averaged 22% in 3Q19
Slide 26: Key Access Agreements to Expand Product Reach
KEY ACCESS AGREEMENTS TO EXPAND PRODUCT REACH DEXYCU® and YUTIQ® added to the Federal Supply Schedule Access to U.S. veterans and other federal agencies Nine Million VA beneficiaries added Three-year agreement for DEXYCU® Vizient’s network includes more than 50% of the nation’s acute care providers,
Slide 27: An Emerging Leader in Ophthalmology
AN EMERGING LEADER IN OPHTHALMOLOGY Transitioned into commercial growth company with the launches of YUTIQ® and DEXYCU® in Q1 2019 Veteran executive team with deep experience in commercial product launches and clinical development Strategic focus to become go-to partner for commercialization in opht
EyePoint Pharmaceuticals — Investor Presentation (January 2020) on 6ix